메뉴 건너뛰기




Volumn 52, Issue 2, 2010, Pages 128-129

Resting heart rate and cardiovascular events: Risk factor or risk marker?

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IVABRADINE;

EID: 77952395214     PISSN: 20786190     EISSN: 20786204     Source Type: Journal    
DOI: 10.1080/20786204.2010.10873951     Document Type: Review
Times cited : (2)

References (8)
  • 1
    • 0023223146 scopus 로고
    • Heart rate and cardiovascular mortality: The Framingham Study
    • Kannel WB, Kannel C, Paffenbarger RSJ, et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987;113:1489-94.
    • (1987) Am Heart J , vol.113 , pp. 1489-1494
    • Kannel, W.B.1    Kannel, C.2    Paffenbarger, R.S.J.3
  • 2
    • 0032917162 scopus 로고    scopus 로고
    • Influence of heart rate on mortality in a French population: Role of age, gender and blood pressure
    • Benetos A, Rudnichi A, Thomas F, et al. Influence of heart rate on mortality in a French population: role of age, gender and blood pressure. Hypertension 1999;33:44-52.
    • (1999) Hypertension , vol.33 , pp. 44-52
    • Benetos, A.1    Rudnichi, A.2    Thomas, F.3
  • 3
    • 18844368814 scopus 로고    scopus 로고
    • Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease
    • Diaz A, Bourassa MG, Guertin MC, et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005;26:967-9.
    • (2005) Eur Heart J , vol.26 , pp. 967-969
    • Diaz, A.1    Bourassa, M.G.2    Guertin, M.C.3
  • 4
    • 0035949564 scopus 로고    scopus 로고
    • Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption
    • Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001;104:1477-82.
    • (2001) Circulation , vol.104 , pp. 1477-1482
    • Heidland, U.E.1    Strauer, B.E.2
  • 5
    • 77749264587 scopus 로고    scopus 로고
    • The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: Results from 135,164 patients in the CRUSADE quality improvement initiative
    • Bangalore S, Messerli FH, Fang-Shu O, et al. The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135,164 patients in the CRUSADE quality improvement initiative. Europ Heart J 2010;31:552-60.
    • (2010) Europ Heart J , vol.31 , pp. 552-560
    • Bangalore, S.1    Messerli, F.H.2    Fang-Shu, O.3
  • 6
    • 70349203826 scopus 로고    scopus 로고
    • Treatment of stable angina pectoris by ivabradine in everyday practice: The REDUCTION study
    • Köster R, Kaehler J, Meinertz T, et al. Treatment of stable angina pectoris by ivabradine in everyday practice: the REDUCTION study. Am Heart J 2009;158:e51-e57.
    • (2009) Am Heart J , vol.158
    • Köster, R.1    Kaehler, J.2    Meinertz, T.3
  • 7
    • 63349103473 scopus 로고    scopus 로고
    • Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta- blocker therapy: A 4-month, randomized, placebo-controlled trial
    • Tardif JC, Ponikowski P, Kahan T. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta- blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009;30:540-548.
    • (2009) Eur Heart J , vol.30 , pp. 540-548
    • Tardif, J.C.1    Ponikowski, P.2    Kahan, T.3
  • 8
    • 50649109186 scopus 로고    scopus 로고
    • Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial
    • Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:807-16.
    • (2008) Lancet , vol.372 , pp. 807-816
    • Fox, K.1    Ford, I.2    Steg, P.G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.